[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, four-period, fully replicated crossover human pharmacokinetic study of atorvastatin calcium tablets in healthy study participants.

主要目的：通过小样本量药代动力学研究，考察石家庄市华新药业有限责任公司的阿托伐他汀钙片（20mg）与持证商为晖致制药（大连）有限公司的阿托伐他汀钙片（20mg）体内药代动力学特征的相似性，为能否进入正式试验提供决策依据，同时考察药物的个体内变异，为正式试验样本量、采血点及分析方法的确定提供证据。次要目的：评价单剂量口服阿托伐他汀钙片（20mg）受试制剂和参比制剂在健康参与者中的安全性。

[Translation]

Primary Objective: To investigate the similarity of pharmacokinetic characteristics between atorvastatin calcium tablets (20 mg) manufactured by Shijiazhuang Huaxin Pharmaceutical Co., Ltd. and those manufactured by Huizhi Pharmaceutical (Dalian) Co., Ltd., through a small-sample pharmacokinetic study. This will provide a basis for decision-making regarding whether to proceed to the formal trial. Simultaneously, it will examine intra-individual variability of the drug, providing evidence for determining the sample size, blood collection points, and analytical methods for the formal trial. Secondary Objective: To evaluate the safety of a single oral dose of atorvastatin calcium tablets (20 mg) in healthy participants, comparing the test and reference formulations.

Start Date01 Jan 2026

Sponsor / Collaborator

Shijiazhuang Huaxin Pharmaceutical Co., Ltd.

ChiCTR2500114776

/ Not yet recruitingNot ApplicableIIT

Research on the Mechanisms of Transsynaptic Degeneration in the Motor System Following Ischemic Stroke and Related Interventions

Start Date01 Jan 2026

Sponsor / Collaborator-

NCT03176498

/ SuspendedPhase 1/2

The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.

This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.

Start Date31 Dec 2025

Sponsor / Collaborator

Sclnow Biotechnology Co., Ltd.

100 Clinical Results associated with Atorvastatin Calcium

100 Translational Medicine associated with Atorvastatin Calcium

100 Patents (Medical) associated with Atorvastatin Calcium

6,773

Literatures (Medical) associated with Atorvastatin Calcium

01 Jan 2026·JAMA Cardiology

Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy

Article

Author: Juhasz, Vencel ; Neuberg, Donna S. ; Quinaglia, Thiago ; Redd, Robert A. ; Ghamari, Azin ; Drobni, Zsofia D. ; Ky, Bonnie ; Heemelaar, Julius C. ; Asnani, Aarti ; Januzzi, James L. ; Neilan, Tomas G. ; Gilman, Hannah K. ; Scherrer-Crosbie, Marielle ; Han, Yuchi ; Brendel, Jan M. ; Mousavi, Negareh ; Kwong, Raymond Y. ; Jerosch-Herold, Michael ; Suero-Abreu, Giselle Alexandra

Importance:

Anthracyclines, which are key to many chemotherapeutic protocols, have been associated with increased vascular stiffness, a major factor associated with cardiovascular morbidity and mortality. There is no evidence-based intervention to prevent anthracycline-associated vascular dysfunction.

Objective:

To investigate whether atorvastatin pretreatment is associated with attenuation of the anthracycline-induced increase in aortic stiffness.

Design, Setting, and Participants:

This study is a secondary analysis of a double-blind, randomized clinical trial (Statins to Prevent the Cardiotoxicity From Anthracyclines [STOP-CA]). Enrollment occurred between January 25, 2017, and September 10, 2021, with the last follow-up on October 10, 2022. Primary analyses were reported on August 8, 2023. STOP-CA was a multicenter trial across 9 academic centers in the US and Canada. Participants were patients with newly diagnosed lymphoma scheduled to undergo anthracycline-based chemotherapy with no clinical indication for a statin.

Intervention:

Atorvastatin (40 mg, once daily) or placebo for 12 months.

Main Outcomes and Measures:

This subanalysis of the STOP-CA trial includes post hoc end points with cardiac magnetic resonance imaging–derived aortic arch pulse wave velocity (PWV) and aortic distensibility (AD). An intention-to-treat approach was applied. The proportions of participants with a 1 SD or more increase in PWV and a 1 SD or more decrease in ascending aortic distensibility (AAD) were calculated in each group over 12 months. An increase in PWV of 0.15 m per second or more, a previously defined annual rate in individuals of similar age, was also assessed as a secondary end point.

Results:

Of the 300 participants (150 randomized to atorvastatin and 150 randomized to placebo), 152 (mean [SD] age, 51 [17] years; 72 female [47%]; 82 treated with atorvastatin) had paired PWV data, and 168 had paired AD data. The PWV values remained similar in the atorvastatin group (mean [SD], 6.5 [1.9] vs 6.5 [2.0] m per second) but increased in the placebo group (5.7 [1.8] vs 6.8 [2.0] m per second) over 12 months. A 1 SD or more increase (0.8 m per second) in PWV was observed among 4 of 82 patients (5%) with atorvastatin and 35 of 70 patients (50%) with placebo (odds ratio, 0.05; 95% CI, 0.02 to 0.16; P &lt; .001) at 12 months. A 1 SD or more decrease (1.8 × 10 −3 mm Hg −1 ) in AAD was observed among 6 of 88 patients (7%) with atorvastatin and in 14 of 80 patients (18%) with placebo. A 1 SD or more increase in PWV was associated with a mean left ventricular ejection fraction decline of 2.70% (95% CI, −4.65% to −0.81%; P = .006).

Conclusions and Relevance:

Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy.

Trial Registration:

ClinicalTrials.gov Identifier: NCT02943590

31 Dec 2025·Islets

Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells

Article

Author: Zhang, Zhiyan ; Zheng, Huadong ; Fan, Jianglin ; Yang, Juan ; Yu, Qi ; Chen, Xiaochang ; Xiang, Aoqi ; Zhang, Lusha ; Guan, Hua ; Su, Peihong

Statins are widely used to treat hyperlipidemia and atherosclerotic cardiovascular diseases (ACVD) by significantly lowering low-density lipoprotein cholesterol (LDL-C) levels. However, their use has been associated with an increased risk of type 2 diabetes (T2D), a paradox given their lipid-lowering benefits. This study investigates the role of LDL receptors (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in the diabetogenic effects of atorvastatin on pancreatic β-cells. Using the MIN6 pancreatic β-cell line, we assessed the impact of atorvastatin on LDL-C uptake, PCSK9 expression, glucose-stimulated insulin release (GSIR), and cell proliferation. Cellular cholesterol assays, EdU labeling, Dil-LDL uptake, western blot analysis, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and ELISA, were employed to measure relevant biomarkers and cellular responses. Male C57BL/6j mice were treated with atorvastatin to validate in vitro findings. Atorvastatin enhances LDL-C uptake by upregulating LDLR on the cell surface, without causing excess cholesterol accumulation. Additionally, atorvastatin suppresses PCSK9 expression, which is crucial for LDLR degradation. Interestingly, atorvastatin, combined with exogenous LDL-C, impairs glucose-stimulated insulin release (GSIR) but promotes cell proliferation, highlighting a potential mechanism for statin-associated diabetes. Oral administration of atorvastatin in mice reduced plasma PCSK9 and insulin levels, supporting the in vitro findings. These results indicate that while atorvastatin effectively lowers circulating cholesterol, it may adversely affect pancreatic β-cell function by modulating LDLR and LDL-C uptake, thereby increasing the risk of T2D. This study highlights the importance of further research to develop strategies mitigating the diabetogenic effects of statins while maintaining their cardiovascular benefits.

02 Nov 2025·Expert Opinion On Drug Safety

Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

Article

Author: Zhang, Rui ; Li, Dongxuan ; Du, Qian ; Zhu, Jun ; Wang, Yalan ; Liu, Songqing ; Dai, Liyang ; Wu, Fan ; Zhang, Tongyan

BACKGROUND:

The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information.

RESEARCH DESIGN AND METHODS:

We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis.

RESULTS:

A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient.

CONCLUSIONS:

Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.

160

News (Medical) associated with Atorvastatin Calcium

21 Jan 2026

·endpoints.news

First-movers respond to biopharma herding into hot targets

There are countless diseases lacking a single good treatment, but drugmakers are still herding into the same targets, particularly in chasing after megablockbusters. George Yancopoulos, the outspoken co-founder and chief scientific officer of Regeneron, is one of the loudest critics of this trend. “Even if they make something you take twice as less frequently, is that what they should be doing?” he said in an interview. “Give me a new drug that treats a new disease.” Herding isn’t new, but it has gotten worse. Only 16% of top drugmakers’ portfolios were in crowded targets in 2000, a percentage that quadrupled by 2020, a McKinsey analysis found . The last few years have only brought more attention to a handful of programs that have pipeline-in-a-product opportunity like Keytruda, Dupixent and Ozempic. Yancopoulos is very aware that Regeneron’s successor plans for Dupixent feature the same target as its best-selling antibody. He said that the Dupixent follow-on research is “not the thing I’m proudest of,” but Regeneron is doing so “out of necessity.” There’s an extended half-life IL-13 antibody and an IL-4/IL-13 bispecific antibody, which could be dosed less frequently than Dupixent. But more importantly to investors, they could protect that franchise from aspiring rival products from biotechs like Apogee Therapeutics and Kymera Therapeutics. “My whole goal is to get the resources to do as much as we can with the best scientists we can,” he told Endpoints News on the sidelines of the JP Morgan Healthcare Conference. “I don’t want some bozos who are going to buy luxury yachts to take investment dollars into R&D that belong to us.” To be sure, it’s a self-interested argument for the company that co-developed Dupixent with Sanofi. Regeneron’s stock fell 9% over last week, with investors concerned about how the biotech will follow up its success with Dupixent and the eye drug Eylea. Markets for obesity and cancer are even more dramatic examples of the crowding. “Welcome to the party,” Eli Lilly CEO David Ricks said during his company’s JPM presentation, responding to an analyst question about future competition on GLP-1s and beyond. Ricks said he believes the “competition makes us better,” planning to win the race with its own pipeline. Meanwhile, Summit Therapeutics is ahead in a race that has exploded for drugs co-targeting PD-1 and VEGF. The company, co-led by the iconoclastic billionaire Bob Duggan and Maky Zanganeh, blasted into the industry’s consciousness in 2024, touting that a late-stage head-to-head study of its drug beat Keytruda in certain lung cancer patients. The next 18 months saw Summit go from relatively alone in pursuing PD-1/VEGF to dozens of biopharmas joining the fray. In 2022, Summit in-licensed its drug, called ivonescimab, from China-based Akeso, which continues to sell the drug in China. Pfizer, Merck, BioNTech and most recently AbbVie have also since in-licensed their own PD-1xVEGF programs from China. “They can’t replicate the insight and the courage to do this,” Duggan said in an interview. “They cannot duplicate ivo as it stands. Carbon, oxygen, hydrogen, nitrogen, sulfur: They can duplicate that, but not the way it’s all laid out. And that’s special.” Summit and Akeso’s drug stands apart by having already treated thousands of patients, Zanganeh added. Combined, they have enrolled 4,000 patients in trials and Akeso has dosed over 60,000 commercial patients in China, Zanganeh said. Summit recently filed for its first US approval, expecting a decision later in 2026. “None of these companies right now, I don’t believe they enroll more than hundreds of patients,” Zanganeh said. The market is mulling that argument. Summit’s stock fell 14% over last week. Some Wall Street analysts are skeptical over the company’s $12.7 billion valuation and if its lead is insurmountable, given far larger and more experienced drugmakers are seeking to catch up. Leerink analyst Daina Graybosch, who holds an underperform rating on Summit, wrote last week there are “few (if any) large-cap pharma companies with sufficient capital and interest to provide upfront consideration for ivo that support [Summit’s] current valuation.” Biopharma execs are split if zeroing in on the same targets is the best use of R&D budgets. Proponents point to the statin race in the 1980s, where Lipitor — the fifth statin to market — ultimately became the class’ bestseller. More recently, Merck’s Keytruda was second to market behind Bristol Myers Squibb’s Opdivo, but has since dominated. Jin-Long Chen, a former Amgen executive who is now a managing partner at Bay Area-based biotech investment group TCG Labs, said it often varies depending on the target and program. He pointed to Keytruda as an example of the real value for latecomers. But as markets become more and more crowded, that argument grows tougher. “That’s not black and white, but if you’re number 10 in targeting the same mechanism, you’re wasting your life,” Chen said.

Drug Approval

20 Dec 2025

·pharma.economictimes.indiatimes.com

Centre draws a price line to curb cheap pharma imports

New Delhi: The Indian government has set a minimum import price (MIP) for certain key pharmaceutical inputs to combat aggressive undercutting and dumping from Chinese manufacturers. The government imposed the floor price restrictions on import of potassium clavulanate , and some intermediates used for the manufacturing of clavulanic acid and potassium clavulanate . Potassium clavulanate is used by the pharmaceutical industry in manufacturing drugs to treat bacterial infections. According to a Directorate General of Foreign Trade (DGFT) notification, the import price of diluted potassium clavulanate or its derivatives is fixed at $180 per KGA. For ATS-8, the imported price is fixed at $111 per kg. ATS-8 is a crucial intermediate used in the synthesis of atorvastatin calcium, a widely prescribed statin for lowering cholesterol levels. The price restrictions will be in place till November 30, 2026, according to the recent notification seen by ET. Henceforth, the import of these raw materials such as bulk drugs or active pharmaceutical ingredients (APIs) will not be allowed below the MIP. However, several pharma industry experts have raised concerns over the government's move to set minimum import prices (MIP), arguing this will artificially raise the cost for manufacturers of both active pharmaceutical ingredients (API) and formulations in India, and lead to an increase in medicine prices for patients. "This price setting decision for clavulanic will be counter-productive since formulation companies were earlier buying the same at $140 per kg. The decision is not based on ground facts," an industry source said. "This is a desperate effort to save companies that have taken the benefit of the government's PLI scheme," the person added, noting the concept of setting a floor price can work only if the entire domestic demand is catered by indigenous suppliers and there is no need of imports, which is not the case here. In November, an MIP of ₹1,174 per kg was announced for sulphadiazine to be effective till September 30 next year. In 2020, the government launched a production-linked incentive (PLI) scheme to draw investments in the manufacturing of critical raw material from the domestic players to reduce the country's dependence on China and bring pricing stability. However, the Chinese started cutting prices further, putting at risk huge investments made by the PLI beneficiaries. Industry insiders add that using MIP is clearly a protectionist tool for PLI beneficiaries and goes beyond the scope of the scheme. By Teena Thacker ,

18 Dec 2025

·www.prnewswire.com

CardioPharma Requests Applications to Investigate the Non-Cardiovascular Benefits of CVD Polypills

WILMINGTON, N.C., Dec. 18, 2025 /PRNewswire/ -- CardioPharma, Inc. (the "Company"), a specialty pharmaceutical company focused on combinatorial drug development for cardiovascular diseases, is seeking applications for secondary analyses of existing datasets to investigate the non-cardiovascular (non-CVD) benefits of the CVD polypill (3 or more medications). While the polypill (fixed-dose combination therapy) is primarily intended for CVD prevention and treatment, emerging evidence suggests potential broader health benefits. This funding opportunity invites investigators to explore these effects, determine how much is mediated by CVD improvements versus direct benefits, and evaluate outcomes in both primary and secondary prevention settings. Dr. Frank Snyder, Chief Medical Officer, stated, "the medical literature has researched and published extensively on the myriad benefits of cardiovascular polypills for years," continuing, "the primary benefits of adherence, safety and efficacy are well known – we want to push our understanding beyond that." Professor of Cardiovascular Medicine at Wake Forest University School of Medicine and CardioPharma Scientific Advisory Board member, Dr. Elsayed Soliman, notes, "Our interest is piqued by the broader potential benefits beyond traditional cardiovascular disease - extending to Alzheimer's disease and related dementias, cognitive decline, cerebral vascular disease including stroke, peripheral vascular disease, chronic kidney disease as well as, potentially, certain ophthalmologic conditions." "By formally commissioning research into these potential non-cardiovascular benefits, CardioPharma is seeking to expand the understanding of how combinatorial cardiovascular medications may benefit less traditional disease states," according to CFO Roy Stimits, "which could benefit an entire new group of patients." CardioPharma's Dr. Daniel Gregory continued, "the global need for these inexpensive medications delivered in a convenient and cost-effective polypill is great. Despite the limited availability in much of the world, this research may help expand patient access by demonstrating even greater need." CardioPharma is dedicated to bringing innovative cardiovascular fixed-dose combinations to markets around the world. Investigators are invited to apply starting February 15, 2026. Further information is available at: CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma, Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for physicians and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit cardiopharma.com or contact Dr. Daniel Gregory [email protected] Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. SOURCE CardioPharma, Inc. 21% more press release views with Request a Demo

AHA

100 Deals associated with Atorvastatin Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D02258	Atorvastatin Calcium	C10AA05	DBSALT000011

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	United States	Upjohn Manufacturing Ireland Unlimited Co.	02 Mar 2007
Angina Pectoris	United States	Upjohn Manufacturing Ireland Unlimited Co.	21 Sep 2005
Myocardial Infarction	United States	Upjohn Manufacturing Ireland Unlimited Co.	21 Sep 2005
Stroke	United States	Upjohn Manufacturing Ireland Unlimited Co.	21 Sep 2005
Heterozygous familial hypercholesterolemia	United States	Upjohn Manufacturing Ireland Unlimited Co.	18 Oct 2002
Hypercholesterolemia, Familial	Japan	Pfizer Inc.	10 Mar 2000
Hypercholesterolemia, Familial	Japan	Astellas Pharma, Inc.	10 Mar 2000
Hypercholesterolemia, Familial	Japan	Viatris Pharmaceutical GK	10 Mar 2000
Coronary Disease	China	Beijing Jialin Pharmaceutical Co., Ltd.	01 Jan 1999
Hypercholesterolemia	Australia	Aspen Pharmacare Australia Pty Ltd.	25 Sep 1997
Hypertension	Australia	Aspen Pharmacare Australia Pty Ltd.	25 Sep 1997
Homozygous familial hypercholesterolemia	United States	Upjohn Manufacturing Ireland Unlimited Co.	17 Dec 1996
Hyperlipidemia Type IIa	United States	Upjohn Manufacturing Ireland Unlimited Co.	17 Dec 1996
Hyperlipoproteinemia Type IIb	United States	Upjohn Manufacturing Ireland Unlimited Co.	17 Dec 1996
Hyperlipoproteinemia Type III	United States	Upjohn Manufacturing Ireland Unlimited Co.	17 Dec 1996
Hyperlipoproteinemia Type IV	United States	Upjohn Manufacturing Ireland Unlimited Co.	17 Dec 1996
Primary hypercholesterolemia	United States	Upjohn Manufacturing Ireland Unlimited Co.	17 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	Phase 3	Thailand	Pfizer Inc.	01 Jan 2014
Immune Reconstitution Inflammatory Syndrome	Phase 3	Thailand	Pfizer Inc.	01 Jan 2014
Tuberculosis	Phase 3	Thailand	Pfizer Inc.	01 Jan 2014
Diabetes Mellitus, Type 2	Phase 3	Malaysia	GSK Plc	01 Dec 2011
Diabetes Mellitus, Type 2	Phase 3	Mexico	GSK Plc	01 Dec 2011
Diabetes Mellitus, Type 2	Phase 3	Philippines	GSK Plc	01 Dec 2011
Diabetes Mellitus, Type 2	Phase 3	Russia	GSK Plc	01 Dec 2011
Diabetes Mellitus, Type 2	Phase 3	South Korea	GSK Plc	01 Dec 2011
Diabetes Mellitus, Type 2	Phase 3	Thailand	GSK Plc	01 Dec 2011
Diabetes Mellitus, Type 1	Phase 3	United States	Pfizer Inc.	01 Oct 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02943590 (STOP-CA, Pubmed \| JAMA Cardiol)	Phase 2	Lymphoma	300	Atorvastatin 40 mg	jvypydrjdk(pfuokkjxma) = eieeugvzgp kofteeqylb (yvbuvvjtht ) View more	Positive	08 Nov 2025
				Placebo	jvypydrjdk(pfuokkjxma) = fckykuyfev kofteeqylb (yvbuvvjtht ) View more
NCT05567068 (Pubmed \| Front Pharmacol)	Phase 2	Colitis, Ulcerative	54	5-ASA plus Atorvastatin	ocehwptpye(yrzwvreyke): P-Value = 0.027 View more	Positive	29 Oct 2025
				5-ASA plus placebo
NCT02603328 (AT CASH EPOC, Pubmed \| Neurosurgery)	Phase 2	Cavernous Hemangioma	100	Atorvastatin	nhguiybgfp(ocfejkyjov) = ytcqrvxjxq zqjzfrgfpm (sdmbgdqabz, 65.0)	Negative	21 Oct 2025
				Placebo	nhguiybgfp(ocfejkyjov) = gabndaylos zqjzfrgfpm (sdmbgdqabz, 94.0)
NCT01988571 (Preventing Anthracycline Cardiovascular Toxicity With Statins, Pubmed \| JAMA Netw Open)	Phase 3	Breast Cancer \| Lymphoma	238	Atorvastatin 40 mg	ojjyyksxnf(dycrpdnloh) = uamldlnkhb suqhyxxhnm (oczjxwocpu, 2.69 - 6.79) View more	Positive	21 Oct 2025
				Placebo	ojjyyksxnf(dycrpdnloh) = duhbuacmyc suqhyxxhnm (oczjxwocpu, 1.71 - 5.54) View more
NCT03308578 (Pubmed \| Am J Hypertens)	Phase 2	Sleep Apnea, Obstructive	39	High-Intensity Atorvastatin	fsfhlbvbdy(mvhmvcdqup): P-Value = 0.51 View more	Negative	10 Oct 2025
				Placebo
NCT02603328 (AT CASH EPOC, CTgov)	Phase 1/2	Hemorrhage \| Central Nervous System Cavernous Hemangioma	80	Atorvastatin (Treatment)	gsvzzmesyy(qbxvutbkzv) = sglepwmhda zmdiqcolyo (lducyzenff, 9.77) View more	-	22 Aug 2025
				Placebo (Placebo)	gsvzzmesyy(qbxvutbkzv) = jcrtmshuxw zmdiqcolyo (lducyzenff, 10.08) View more
IRCT20200825048515N36 (ESMO_GI2025)	Phase 3	Toxicity	64	Atorvastatin 40 mg daily	clgncxksay(svgzrqdflt) = jrxzdcjkpe ceuhoqvukw (ryotrqfwik ) View more	Negative	03 Jul 2025
				Placebo	clgncxksay(svgzrqdflt) = esnwrilcxy ceuhoqvukw (ryotrqfwik ) View more
NCT03360916 (CTgov)	Phase 4	Cardiovascular Diseases \| Hypertension	52	placebo (Placebo)	edinpjurkg(xkapfwansy) = rsjxkdfcan aczsdznfph (ruhbmdqidp, 125.59) View more	-	15 Apr 2025
				Lipitor (Low Dose Statin)	edinpjurkg(xkapfwansy) = bigimvkdsq aczsdznfph (ruhbmdqidp, 130.12) View more
NCT02943590 (STOP-CA, Pubmed \| JACC CardioOncol)	Phase 2	Cardiotoxicity \| Lymphoma	171	Atorvastatin	femuwihdkw(oprzahuhvc) = fefsqwzekg rxlxjbgofi (awbrvvkqyk )	Positive	01 Feb 2025
				Placebo	femuwihdkw(oprzahuhvc) = uxbqypjike rxlxjbgofi (awbrvvkqyk )
NCT02943590 (STOP-CA, Pubmed \| J Cardiovasc Magn Reson)	Phase 2	Lymphoma	158	Atorvastatin	gjxqltlffa(uyqymdkxxm): P-Value = 0.59 View more	Negative	01 Jan 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis